Belnord Capital

Overview

Belnord Capital is an independent alternative investment firm based in Stockholm, Sweden, specializing in GP-led solutions across secondaries and co-investments. The firm focuses on forging strategic partnerships with European mid-market private equity managers, leveraging a hands-on investment approach and a strong network to unlock high-quality deal flow. As committed investors, Belnord Capital invests significant capital into its own funds, ensuring alignment with its partners. The firm's investment strategy includes sponsor-led transactions, continuation vehicles, direct investments, co-investments, and other liquidity solutions. Belnord Capital's portfolio encompasses companies such as Medix Biochemica, a global leader in critical components for diagnostic tests; Immedica, a pharmaceutical company specializing in rare diseases and specialty care; Yaveon, an independent software vendor specializing in Microsoft Dynamics Business Central; and Syclef, a European leader in the installation and maintenance of refrigeration and air conditioning systems. Belnord Capital closed its inaugural fund, Belnord Capital Fund I, with €265 million in commitments, surpassing its €250 million target. The oversubscribed fund attracted a diverse group of investors, including institutions, family offices, entrepreneurs, and the Belnord Capital team itself. The fund is approximately 50% invested, demonstrating the firm's differentiated and innovative investment style. Belnord Capital leverages extensive direct investing expertise to outperform in the secondary market, positioning itself as a trusted partner for GPs seeking long-term alignment.

Investment Focus

• Focus on European mid-market private equity managers
• Interest in GP-led solutions across secondaries and co-investments
• Alignment with Belnord Capital's hands-on investment approach and strong network

Portfolio Companies